Literature DB >> 34596743

Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.

Jordi Río1, Àlex Rovira2, Claudio Gasperini3, Mar Tintoré4, Luca Prosperini3, Susana Otero-Romero4, Manuel Comabella4, Ángela Vidal-Jordana4, Ingrid Galán4, Luciana Midaglia4, Breogán Rodriguez-Acevedo4, Ana Zabalza4, Joaquim Castilló4, Georgina Arrambide4, Carlos Nos4, Álvaro Cobo4, Carmen Tur4, Cristina Auger2, Jaume Sastre-Garriga4, Xavier Montalban4.   

Abstract

BACKGROUND AND OBJECTIVES: Different treatment response scoring systems in treated MS patients exist. The objective was to assess the long-term predictive value of these systems in RRMS patients treated with self-injectable DMTs.
METHODS: RRMS-treated patients underwent brain MRI before the onset of therapy and 12 months thereafter, and neurological assessments every 6 months. Clinical and demographic characteristics were collected at baseline. After the first year of treatment, several scoring systems [Rio score (RS), modified Rio score (MRS), MAGNIMS score (MS), and ROAD score (RoS)] were calculated. Cox-Regression and survival analyses were performed to identify scores predicting long-term disability.
RESULTS: We included 319 RRMS patients. Survival analyses showed that patients with RS > 1 and RoS > 3 had a significant risk of reaching an EDSS of 4.0 and 6.0 The score with the best sensitivity (61%) was the RoS, while the MRS showed the best specificity (88%). The RS showed the best positive predictive value (42%) and the best accuracy (81%).
CONCLUSIONS: The combined measures integrated into different scores have an acceptable prognostic value for identifying patients with long-term disability. Thus, these data reinforce the concept of early treatment optimization to minimize the risk of long-term disability.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Multiple sclerosis; Scores; Treatment response

Mesh:

Year:  2021        PMID: 34596743     DOI: 10.1007/s00415-021-10823-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  2 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

2.  Dengue fever in a multiple sclerosis patient taking Ocrelizumab.

Authors:  Tommaso Guerra; Luca Bollo; Maria Trojano; Pietro Iaffaldano
Journal:  Mult Scler       Date:  2021-08-27       Impact factor: 6.312

  2 in total
  1 in total

1.  Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohort.

Authors:  Maximilian Pistor; Helly Hammer; Anke Salmen; Robert Hoepner; Christoph Friedli
Journal:  CNS Neurosci Ther       Date:  2022-01-21       Impact factor: 5.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.